Shots:

• J&J and the US Department of Health and Human Services have expanded an agreement to support the next phase of COVID-19 vaccine candidate research and development
• Janssen will commit ~$604M while BARDA will commit ~$454M to support the ongoing P-lll ENSEMBLE study assessing Janssen’s JNJ-78436735 as a single-dose in ~60-000 patients globally
• J&J affirmed its commitment to develop and test its vaccine candidate in accordance with high ethical standards and sound scientific principles- as outlined in a pledge made by 9 vaccine manufacturers in early 2020

­  Ref: PR Newswire | Image: Courier Journal